Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting
TEL AVIV, Israel, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that an additional presentation highlighting the clinical study design for its planned Phase 3 registrational trial of EB613 (oral PTH(1-34) tablet) will be presented at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting, taking place October 9-12, 2026, at the John B. Hynes Veterans Memorial Convention Center in Boston, Massachusetts.
Covered in this story
What has happened since
- TE Connectivity is down 1.2% since this was published, 12 days ago.
- Entera Bio is up 27.6% since this was published, 12 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on TE Connectivity
- Bernstein: $214 → $243 by Sep 2027 · Outperform via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $TEL yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on TE Connectivity →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.